English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background    Mycobacterium tuberculosis  causes the majority of tuberculosis (TB) cases in humans; however, in developing countries, human TB caused by  M .  bovis  may be frequent but undetected. Human TB caused by M.  bovis  is considered a zoonosis; transmission is mainly through consumption of unpasteurized dairy products, and it is less frequently attributed to animal-to-human or human-to-human contact. We describe the trends of  M .  bovis  isolation from human samples and first-line drug susceptibility during a 15-year period in a referral laboratory located in a tertiary care hospital in Mexico City.    Methodology/Principal Findings  Data on mycobacterial isolates from human clinical samples were retrieved from the laboratory’s database for the 2000–2014 period. Susceptibility to first-line drugs: rifampin, isoniazid, streptomycin (STR) and ethambutol was determined. We identified 1,165 isolates, 73.7% were  M .  tuberculosis  and 26.2%,  M .  bovis . Among pulmonary samples, 16.6% were  M .  bovis . The proportion of  M .  bovis  isolates significantly increased from 7.8% in 2000 to 28.4% in 2014 ( X    2    trend , p<0.001). Primary STR resistance was higher among  M .  bovis  compared with  M .  tuberculosis  isolates (10.9% vs.3.4%, p<0.001). Secondary multidrug resistance (MDR) rates were 38.5% and 34.4% for  M .  bovis  and  M .  tuberculosis , respectively (p = 0.637). A rising trend of primary STR monoresistance was observed for both species (3.4% in 2000–2004 vs. 7.6% in 2010–2014; p = 0.02).    Conclusions/Significance  There is a high prevalence and a rising trend of  M .  bovis  isolates in our region. The proportion of pulmonary  M .  bovis  isolates is higher than in previous reports. Additionally, we report high rates of primary anti-tuberculosis resistance and secondary MDR in both  M .  tuberculosis  and  M .  bovis . This is one of the largest reports on drug susceptibility of  M .  bovis  from human samples and shows a significant proportion of first-line anti-tuberculosis drug resistance.

Trends of Mycobacterium bovis Isolation and First-Line Anti-tuberculosis Drug Susceptibility Profile: A Fifteen-Year Laboratory-Based Surveillance